Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103


Cost-effectiveness analysis of mechanical thrombectomy plus tissue-type plasminogen activator compared with tissue-type plasminogen activator alone for acute ischemic stroke in France.

Kaboré N, Marnat G, Rouanet F, Barreau X, Verpillot E, Menegon P, Maachi I, Berge J, Sibon I, Bénard A.

Rev Neurol (Paris). 2019 Jan 11. pii: S0035-3787(18)30411-9. doi: 10.1016/j.neurol.2018.06.007. [Epub ahead of print]


Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy.

Ruggeri M, Basile M, Zini A, Mangiafico S, Agostoni EC, Lobotesis K, Saver J, Coretti S, Drago C, Cicchetti A.

J Med Econ. 2018 Sep;21(9):902-911. doi: 10.1080/13696998.2018.1484748. Epub 2018 Jun 28.


A cost-utility analysis of mechanical thrombectomy as an adjunct to intravenous tissue-type plasminogen activator for acute large-vessel ischemic stroke.

Kim AS, Nguyen-Huynh M, Johnston SC.

Stroke. 2011 Jul;42(7):2013-8. doi: 10.1161/STROKEAHA.110.606889. Epub 2011 Jun 2.


Would a Large tPA Trial for Those 4.5 to 6.0 Hours from Stroke Onset Be Good Value for Information?

Soeteman DI, Menzies NA, Pandya A.

Value Health. 2017 Jul - Aug;20(7):894-901. doi: 10.1016/j.jval.2017.03.004. Epub 2017 Apr 29.


Cost-effectiveness of mechanical thrombectomy within 6 hours of acute ischaemic stroke in China.

Pan Y, Cai X, Huo X, Zhao X, Liu L, Wang Y, Miao Z, Wang Y.

BMJ Open. 2018 Feb 22;8(2):e018951. doi: 10.1136/bmjopen-2017-018951.


Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke.

Tung CE, Win SS, Lansberg MG.

Stroke. 2011 Aug;42(8):2257-62. doi: 10.1161/STROKEAHA.111.615682. Epub 2011 Jun 30.


Cost-effectiveness analysis of tissue plasminogen activator in acute ischemic stroke in Iran.

Amiri A, Goudarzi R, Amiresmaili M, Iranmanesh F.

J Med Econ. 2018 Mar;21(3):282-287. doi: 10.1080/13696998.2017.1401545. Epub 2017 Nov 28.


Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China.

Pan Y, Chen Q, Zhao X, Liao X, Wang C, Du W, Liu G, Liu L, Wang C, Wang Y, Wang Y; TIMS-CHINA Investigators.

PLoS One. 2014 Oct 20;9(10):e110525. doi: 10.1371/journal.pone.0110525. eCollection 2014.


Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke.

Ganesalingam J, Pizzo E, Morris S, Sunderland T, Ames D, Lobotesis K.

Stroke. 2015 Sep;46(9):2591-8. doi: 10.1161/STROKEAHA.115.009396. Epub 2015 Aug 6.


Cost-effectiveness of stent-retriever thrombectomy in combination with IV t-PA compared with IV t-PA alone for acute ischemic stroke in the UK.

Lobotesis K, Veltkamp R, Carpenter IH, Claxton LM, Saver JL, Hodgson R.

J Med Econ. 2016 Aug;19(8):785-94. doi: 10.1080/13696998.2016.1174868. Epub 2016 Apr 21.


Cost-effectiveness of mechanical thrombectomy for acute ischemic stroke: an Australian payer perspective.

Arora N, Makino K, Tilden D, Lobotesis K, Mitchell P, Gillespie J.

J Med Econ. 2018 Aug;21(8):799-809. doi: 10.1080/13696998.2018.1474746. Epub 2018 May 30.


Mechanical thrombectomy in patients with acute ischemic stroke: a cost-utility analysis.

Xie X, Lambrinos A, Chan B, Dhalla IA, Krings T, Casaubon LK, Lum C, Sikich N, Bharatha A, Pereira VM, Stotts G, Saposnik G, O'Callaghan C, Kelloway L, Hill MD.

CMAJ Open. 2016 Jun 16;4(2):E316-25. doi: 10.9778/cmajo.20150088. eCollection 2016 Apr-Jun.


Cost-effectiveness analysis of mechanical thrombectomy in acute ischemic stroke.

Patil CG, Long EF, Lansberg MG.

J Neurosurg. 2009 Mar;110(3):508-13. doi: 10.3171/2008.8.JNS08133.


Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence.

Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, Veenstra DL.

Stroke. 2014 Oct;45(10):3032-9. doi: 10.1161/STROKEAHA.114.005852. Epub 2014 Sep 4.


Mechanical Thrombectomy in Patients With Acute Ischemic Stroke: A Health Technology Assessment.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2016 Feb 8;16(4):1-79. eCollection 2016.


Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke: Results From the SWIFT-PRIME Trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke).

Shireman TI, Wang K, Saver JL, Goyal M, Bonafé A, Diener HC, Levy EI, Pereira VM, Albers GW, Cognard C, Hacke W, Jansen O, Jovin TG, Mattle HP, Nogueira RG, Siddiqui AH, Yavagal DR, Devlin TG, Lopes DK, Reddy VK, du Mesnil de Rochemont R, Jahan R, Vilain KA, House J, Lee JM, Cohen DJ; SWIFT-PRIME Investigators.

Stroke. 2017 Feb;48(2):379-387. doi: 10.1161/STROKEAHA.116.014735. Epub 2016 Dec 27.


Cost-Effectiveness of Intra-Arterial Treatment as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke.

Leppert MH, Campbell JD, Simpson JR, Burke JF.

Stroke. 2015 Jul;46(7):1870-6. doi: 10.1161/STROKEAHA.115.009779. Epub 2015 May 26.


Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.

Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, Albers GW, Cognard C, Cohen DJ, Hacke W, Jansen O, Jovin TG, Mattle HP, Nogueira RG, Siddiqui AH, Yavagal DR, Devlin TG, Lopes DK, Reddy V, du Mesnil de Rochemont R, Jahan R; SWIFT PRIME Investigators.

Int J Stroke. 2015 Apr;10(3):439-48. doi: 10.1111/ijs.12459.


Age-specific Cost Effectiveness of Using Intravenous Recombinant Tissue Plasminogen Activator for Treating Acute Ischemic Stroke.

Joo H, Wang G, George MG.

Am J Prev Med. 2017 Dec;53(6S2):S205-S212. doi: 10.1016/j.amepre.2017.06.004.

Supplemental Content

Support Center